She pioneered the discovery of nucleoside analogs induced centrosomal amplification and aneuploidy while working as a senior staff scientist at the National Cancer Institute (NCI).

With her colleagues, she showed for the first time that the nucleoside analog used in the earliest AIDS therapy by pregnant women to prevent the vertical transmission of HIV from the mother to the fetus was a transplacental carcinogen in mice.

[1] She pioneered the discovery of nucleoside analogs induced centrosomal amplification and aneuploidy working as a senior staff scientist in the Laboratory of Cancer Biology and Genetics at the NCI.

[2] Olivero has been an active member of the National Institutes of Health (NIH) SACNAS Chapter, the NIH and HHS Hispanic Employee Organization (HEO), and a long-standing member of the American Association for Cancer Research, where she participates in their minority and women in cancer research special groups.

Olivero was an active member of the NIH Hispanic and Latino Committee (HLEC) sponsored by NIH Office of Equality Diversity and Inclusion (EDI), and an advisor at various chief officer for scientific workforce diversity (COSWD) scientific recruitment and careers subcommittees.